Compare CFBK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFBK | NERV |
|---|---|---|
| Founded | 1892 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.1M | 210.1M |
| IPO Year | 2005 | 2014 |
| Metric | CFBK | NERV |
|---|---|---|
| Price | $30.11 | $4.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $31.50 | $10.50 |
| AVG Volume (30 Days) | 44.0K | ★ 117.8K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 30.58 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $31.99 | N/A |
| Revenue Next Year | $9.09 | N/A |
| P/E Ratio | $38.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.10 | $1.57 |
| 52 Week High | $34.34 | $12.46 |
| Indicator | CFBK | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 32.13 |
| Support Level | $28.40 | $3.69 |
| Resistance Level | $30.25 | $4.59 |
| Average True Range (ATR) | 0.91 | 0.37 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 54.13 | 15.00 |
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.